Wells Fargo’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Wells Fargo’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8	Closed	-$180	–	7812
2023 Q2	$180	Hold	8	–	–	﹤0.01%	6731
2023 Q1	$96	Hold	8	–	–	﹤0.01%	6947
2022 Q4	$36	Hold	8	–	–	﹤0.01%	7113
2022 Q3	$0	Hold	8	–	–	﹤0.01%	7754
2022 Q2	$0	Sell	8 -682	-99%	-$9.17K	﹤0.01%	7851
2022 Q1	$13K	Sell	690 -410	-37%	-$9.14K	﹤0.01%	6189
2021 Q4	$39K	Sell	1,100 -5,622	-84%	-$320K	﹤0.01%	6087
2021 Q3	$494K	Buy	6,722 +5,459	+432%	+$420K	﹤0.01%	4670
2021 Q2	$176K	Buy	1,263 +1,078	+583%	+$189K	﹤0.01%	5081
2021 Q1	$54K	Buy	+185	New	+$73.5K	﹤0.01%	5782

Other funds holding SGTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wells Fargo's SGTX Position: Q3 2023 in Review

Wells Fargo sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2023, closing a stake of 8 shares — an estimated $180 sold.

Wells Fargo first reported a position in SGTX in Q1 2021 and held it in 10 quarters. The position peaked at $494K in Q3 2021. 1 fund tracked by Wall St. Rank holds SGTX as of Q3 2023.

Wells Fargo reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Wells Fargo sold 8 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $180.
Wells Fargo first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
Wells Fargo's Sigilon Therapeutics, Inc. Common Stock position peaked at $494K in Q3 2021.
1 fund tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.